Hif‐1alpha stabilisation is protective against infection in zebrafish comorbid models

Multi‐drug‐resistant tuberculosis is a worldwide problem, and there is an urgent need for host‐derived therapeutic targets, circumventing emerging drug resistance. We have previously shown that hypoxia‐inducible factor‐1α (Hif‐1α) stabilisation helps the host to clear mycobacterial infection via neutrophil activation. However, Hif‐1α stabilisation has also been implicated in chronic inflammatory diseases caused by prolonged neutrophilic inflammation. Comorbid infection and inflammation can be found together in disease settings, and it remains unclear whether Hif‐1α stabilisation would be beneficial in a holistic disease setting. Here, we set out to understand the effects of Hif‐1α on neutrophil behaviour in a comorbid setting by combining two well‐characterised in vivo zebrafish models – TB infection (Mycobacterium marinum infection) and sterile injury (tailfin transection). Using a local Mm infection near to the tailfin wound site caused neutrophil migration between the two sites that was reduced during Hif‐1α stabilisation. During systemic Mm infection, wounding leads to increased infection burden, but the protective effect of Hif‐1α stabilisation remains. Our data indicate that Hif‐1α stabilisation alters neutrophil migration dynamics between comorbid sites and that the protective effect of Hif‐1α against Mm is maintained in the presence of inflammation, highlighting its potential as a host‐derived target against TB infection

Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses

To understand neurological complications of COVID-19 better both acutely and for recovery, we measured markers of brain injury, inflammatory mediators, and autoantibodies in 203 hospitalised participants; 111 with acute sera (1–11 days post-admission) and 92 convalescent sera (56 with COVID-19-associated neurological diagnoses). Here we show that compared to 60 uninfected controls, tTau, GFAP, NfL, and UCH-L1 are increased with COVID-19 infection at acute timepoints and NfL and GFAP are significantly higher in participants with neurological complications. Inflammatory mediators (IL-6, IL-12p40, HGF, M-CSF, CCL2, and IL-1RA) are associated with both altered consciousness and markers of brain injury. Autoantibodies are more common in COVID-19 than controls and some (including against MYL7, UCH-L1, and GRIN3B) are more frequent with altered consciousness. Additionally, convalescent participants with neurological complications show elevated GFAP and NfL, unrelated to attenuated systemic inflammatory mediators and to autoantibody responses. Overall, neurological complications of COVID-19 are associated with evidence of neuroglial injury in both acute and late disease and these correlate with dysregulated innate and adaptive immune responses acutely